Pfizer (PFE) PT Raised to $42 at BofA Securities After Supportive FDA Review of Covid Vaccine
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham raised the price target on Pfizer (NYSE: PFE) to $42.00 (from $39.00) after the FDA’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
